SciSparc Ltd. has received renewed approval from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210 in children with autism spectrum disorder (ASD).
SciSparc has enrolled the first patient in its clinical trial for SCI-210, a cannabinoid-based treatment for Autism Spectrum Disorder (ASD) in children.
SciSparc's SCI-110 receives FDA approval to proceed with Phase IIb clinical trials for Tourette Syndrome treatment, marking a key advancement for the company.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.